Table 3.
PsA treatment at study visit
| Total | MDA | No MDA | p | |
|---|---|---|---|---|
| Treatment pattern, n (%) | NS | |||
| Anti-TNF monotherapy | 110 | 69 (62.7) | 41 (37.3) | |
| DMARDS and anti-TNF | 61 | 32 (52.5) | 29 (47.5) | |
| DMARDS monotherapy | 51 | 32 (62.7) | 19 (37.3) | |
| Anti-TNF*, n (%) | 112 | 64 (57.1) | 48 (42.9) | NS |
| Etanercept | 42 | 26 (61.9) | 16 (38.1) | |
| Adalimumab | 35 | 22 (62.9) | 13 (37.1) | |
| Infliximab | 15 | 6 (40.0) | 9 (60.0) | |
| Golimumab | 13 | 7 (53.8) | 6 (46.2) | |
| Mean (SD) time, months | 45.7 (34.7) | 50.5 (35.0) | 40.2 (33.8) | NS |
| DMARDS*, n (%) | 171 | 101 (59.1) | 70 (40.9) | NS |
| Metotrexate | 130 | 76 (58.5) | 54 (41.5) | |
| Leflunomide | 32 | 17 (53.1) | 15 (46.9) | |
| Mean (SD) time, months | 73.7 (70.4) | 71.8 (71.8) | 76.4 (69.7) | NS |
| NSAIDs**, n (%) | 114 | 62 (54.4) | 52 (45.6) | NS |
| Infiltrations**, n (%) | 48 | 27 (56.3) | 21 (43.8) | NS |
| Corticoids**, n (%) | 39 | 16 (41.0) | 23 (59.0) | <0.05 |
*Monotherapy or combination therapy
**Combination therapy
anti-TNF anti-tumor necrosis factor, DMARDS disease-modifying anti-rheumatic drugs, NS not significant, NSAIDs nonsteroidal anti-inflammatory drugs